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Background Various information technologies currently are used to improve the 
efficiency of clinical trials. However, electronic medical records (EMRs) are not yet 
linked to the electronic data capture (EDC) system. Therefore, the data must be extracted 
from medical records and transcribed to the EDC system. Clinical pathways are planned 
process patterns that are used in routine clinical practice and are easily applicable to the 
medical care and evaluation defined in a trial protocol. However, few clinical pathways 
are intended to increase the efficiency of clinical trials. 
 
Purpose Our purpose is to describe the design and development of a new clinical trial 
process model that enables the primary use of EMRs in clinical trials by integrating 
clinical pathways and EMRs. 
 
Methods We designed a new clinical trial model that uses EMR data directly in clinical 
trials and developed a system to follow this model. We applied the system to an 
investigator-initiated clinical trial and examined whether all data were extracted 
correctly. At the protocol development stage, our model measures endpoints based on 
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clinical pathways with the same diagnosis. Next, medical record descriptions and the 
format of the statistical data are defined. According to these observations, screens to 
entry data which is used for both in clinical practice and for study are prepared into 
EMRs with an EMR template, and screens are prepared for data checks on our EMR 
retrieval system (ERS). In an actual trial, patients are registered and randomly assigned 
to a protocol treatment. The protocol treatment is executed according to clinical 
pathways, and the data are recorded to EMRs using EMR templates. The data are 
checked by a local data manager using reports created by the ERS. After edit checks and 
corrections, the data are extracted by the ERS, archived in portable document format 
(PDF) with an electronic signature, and transferred in comma separated values format 
(CSV) to a coordinating centre. At the coordinating centre, the data are checked, 
integrated, and made available for statistical analysis. 
 
Results We verified that the data could be extracted correctly and found no unexpected 
problems. 
 
Limitation To execute clinical trials in our system, the EMR template and efficient 
EMR retrieval systems are required. Additionally, to execute multi-institutional clinical 
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trials, it is necessary to create templates appropriate for EMRs at all participating sites 
and for the coordinating centre to validate local templates and procedures. 
  
Conclusion We proposed and pilot tested a new eClinical trial model. Because our 
model is integrated with routine documentation of clinical practice and clinical trials, 
redundant data entries were avoided and the burden on the investigator was minimised. 
The reengineering of the clinical trial process would facilitate the establishment of 
evidence in the future. 
 
Keywords 





To improve the efficiency of clinical trials, evaluating and restructuring the 
information-capture process and the flow of data are critical [1-3]. In many clinical trials, 
paper-based case report forms (CRFs) are developed for each clinical trial protocol and 
information is transcribed from source documents, including medical records, to CRFs 
and from CRFs to the clinical data management system (CDMS). Thus, mistranscriptions 
and inconsistencies are inevitable in this dual transcription process [2, 4]. Various 
information technologies currently are used to improve the efficiency of clinical trials, 
including computerised registration systems, CDMS, and electronic data capture (EDC) 
systems, among others [2, 4-5]. Elsewhere, medical information technology recently has 
been promoted. The electronic medical record (EMR) system has been launched in 
approximately 20% of all institutions in Japan. However, EMRs are not yet linked to the 
EDC system for clinical research; therefore, the clinical trial staff must manually select 
the necessary information from EMRs and transcribe it into the EDC system [2]. Thus, 
the workload at each participating site has not changed with the transition from 
paper-based CRFs to EDC systems, and there has been no breakthrough in efficiency [2]. 
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The president of the Clinical Data Interchange Standards Consortium (CDISC), 
Rebecca Daniels Kush, named the next generation of clinical trials ‘eClinical trials’ [3]. 
She emphasized the importance of optimising clinical trials by redesigning the trial 
process to utilise primarily electronic processes and to coordinate hospital information 
systems with the various clinical trials systems [3]. In addition, the CDISC’s Electronic 
Source Data Interchange (eSDI) initiative, encouraged by the US Food and Drug 
Administration, was started in 2004 [4]. The eSDI detailed the regulatory requirements 
and outlined promising scenarios concerning clinical trials using electronic source data 
(eSource), such as electronic subject diaries, electronic laboratory results, and EMRs. 
To enhance clinical trials utilising eSource, the eSDI analysed the present regulatory 
requirements, compiled 12 indispensable requirements, outlined five scenarios that 
would fit the regulatory requirements, and formed a proposal.  
 
Currently, most clinical trials including standards-based approaches that use data from 
EMRs are planned according to the concept that the primary use of EMRs is in clinical 
practice and a secondary use is clinical research [6-11]. To use EMR data secondarily in 
a clinical trial, it is necessary to obtain various types of information that are stored in 
EMRs by category, such as the diagnosis and medications taken. However, extraction of 
 8 
this information is not facilitated by the current EMR system [11-13]. Moreover, not all 
information that is necessary to execute a clinical trial typically is stored in the EMR [6, 
10-12]. If EMRs are used only for the purpose of collecting certain receipts of claims 
and the treatments for each patient, enough information may be stored in the current 
EMRs. However, if there is a secondary intention to use the accumulated information 
from EMRs in clinical research, then the data that are not gathered specifically for 
research purposes may be incomplete and unreliable [6, 11-12]. To improve the 
efficiency of clinical trials, it is necessary to establish a method that utilises EMRs 
directly in clinical trials and enables higher levels of information-sharing and exchange 
between clinical practice and clinical trials [1-3].  
 
Clinical pathways have been introduced in clinical practice [14, 15]. Clinical pathways 
are planned process patterns aimed at improving both process quality and resource usage 
[14, 15]. Clinical pathways include components such as a timeline, the categories of care 
or activities, and the interventions for specified groups of patients with a particular 
diagnosis. They are widely used as a treatment plan or as a substitute for physicians’ 
orders [14, 15]. Clinical pathways appear to be easily applicable to the protocol treatment 
of a clinical trial because they deliver a standard of care to patients with a specific disease 
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[14, 15]. However, there are few clinical pathways that purport to improve the efficiency 




Our purpose is to develop a new clinical trial process model that enables the primary use 
of EMRs in a clinical trial by integrating clinical pathways and EMRs. We report herein 
on a pilot test of our model in a single-centre clinical trial conducted at our institution. 
 
METHODS 
Methods and outline of our model of the clinical trial process 
 
We modelled a new clinical trial process in which practical medical records are used 
directly in clinical trials and developed a clinical trial system to follow our model. We 
applied the new system to an investigator-initiated clinical trial and examined whether 
all of the data needed to conduct the clinical trial were extracted correctly throughout 
the system. Moreover, by comparing the new model with the conventional method of 
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conducting clinical trials, we made a qualitative observation of how the new model 
reduces the workload in clinical trials.  
 
In our model, a clinical trial is performed as follows (see also Figure 1): 
 
1. In the protocol development stage, the methods of measuring endpoints (i.e., protocol 
treatment and evaluation items) are decided based on the clinical pathways that usually 
are used for patients with the same diagnosis. Next, medical record descriptions are 
defined, including eligibility criteria, tests, protocol treatment, efficacy of treatment, 
adverse events and follow-up. At the same time, the data format and coding conventions 
for the statistical data are defined to be compatible with statistical software. For 
example, the description of adverse events is synchronised and standardised with 
clinical practice and clinical trials according to the Common Terminology Criteria for 
Adverse Events (CTCAE) [16]. 
2. According to the defined descriptions, screens are prepared for entry of the additional 
data required for the clinical trial into EMRs using EMR templates, and screens are 
prepared for data checks and data extraction by our EMR retrieval system (ERS). The 
templates are named to enable clinicians to identify them as pertaining only to the trial. 
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3. Patients who provide informed consent and agree to participate are registered and  
randomly assigned to one of the protocol treatments. 
4. The protocol treatment assigned to the patient is executed according to clinical 
pathways, and the treatment data are recorded to EMRs using EMR templates. 
5. Data are extracted using the ERS and are checked automatically for completeness and 
consistency and to identify anomalies to be resolved. 
6. After edit checks have been satisfied following corrections, the data are extracted by 
the ERS, archived in portable document format (PDF) with an electronic signature, and 
transferred in comma separated values format (CSV) to a coordinating centre.  
7. At the coordinating centre, the clinical trial data from participating sites are checked, 
integrated, and made available for statistical analysis. 
 
When it is necessary to update trial data that already have been transferred to the 
coordinating centre, the process repeats from when the investigator updates the medical 
records using the clinical trials template. In addition, central pathology reviews or 
central laboratory findings are integrated with clinical data in the coordinating centre. 
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Because our new model is integrated, with the routine documentation of clinical 
practice and the procedures of clinical trials, to avoid redundant data entries, the 
efficiency of clinical trials can be improved. 
 
Applied information technology 
EMR templates 
 
To record clinical trial data to EMRs that could be available for clinical practice, we 
used EMR template technology [14, 17-21].  
 
In the current EMR system in Japan, various types of information are integrated, 
including coded data. Coded data include laboratory results that are in the computerised 
physician order entry system, narrative information, such as observations during 
physical examinations or progress notes that are written in free-text form, radiological 
images, and waveform information from electrocardiograms. In particular, it was 
necessary to convert free-text information to structured information that is expressed by 
data elements consisting of items and values with codes for use in a clinical trial [17]. 
The most practical method is to use a template for entering data into the EMR system 
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[17]. Using templates, the entered narrative information can be made available for data 
analysis. 
  
In Japan, the EMR template technology already has been implemented for most large 
hospitals’ EMR systems, including ours, and is widely used to standardise medical 
records. Although multiple vendors supply various templates, when the new 
information is recorded, our hospital stores key data, such as the template ID, item ID, 
and entry date and time, in the EMR database. Moreover, our EMR system is managed 
according to the Japanese Ministry of Health, Labour and Welfare’s guidelines on 
hospital information system management. To guarantee data integrity, all modifications 
to EMR data are recorded when and by whom each operation is executed, and an audit 
trail is made automatically. Audit trails record whose, when, and by whom medical 
records have been accessed. No user can update audit trails or prevent recording them. 
In addition, after medical records are submitted by medical staff, no user can delete the 
records. When medical records are updated, the new data are created as updated records, 
and the old data are retained as deleted records with a ‘deletion flag’. This traceability 
management function is applied to the clinical trial template; all clinical trial data and 
histories are stored on the EMR system. 
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EMR retrieval system 
 
We use the ERS that was developed in our translational research centre to extract data 
from EMRs, verify the completeness and consistency of trial data, and create output data 
for statistical analysis. The ERS can retrieve data from patients participating in the 
clinical trial comprehensively and efficiently. To retrieve and report the records in 
clinical practice directly as data for clinical research, we identified entities from EMRs 
that are useful for clinical research (i.e., data on patient demographics, diagnosis, 
physical examination, progress notes recorded in the EMR template, operative notes, 
laboratory tests, radiological or pathological studies, medications and injections, and 
other treatments). Next, we designed a multidimensional data model for EMR retrieval 
for clinical research [11, 22-25]. To ensure that the data retrieval process is practical and 
independent from the structure of the EMR system, a data warehouse was created by 
extracting, transforming, and loading information from the EMR system. To retrieve and 
report information from multiple patients efficiently, an online analytical processing 
(OLAP) tool was installed [26]. The OLAP tool runs from an Internet browser and has 
the ability, in hypertext markup language (HTML), to report on information retrieved 
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from the browser. The reports are created in various formats, such as PDF, CSV, and 
extensible markup language (XML). The ERS also was applied to the data recorded 
using the new template. We created reports for checking trial data and extracting data for 
statistical analysis. 
 
Application to a clinical trial 
 
We applied the system to a single-institution phase II trial for hepatocellular carcinoma.  
(‘A randomised controlled study of effectiveness between transcatheter arterial 
chemoembolisation (TACE) with cisplatin and TACE with epirubicin for multiple 
hepatocellular carcinomas’). This study was approved by the ethics committee of Kyoto 
University Hospital and was registered in the UMIN Clinical Trials Registry [27] 
(registration number UMIN000003162). 
 
Based on the findings from an observational study in our hospital [28, 29], this phase II 
trial was designed to confirm the effectiveness of TACE in combination with one of the 
two anticancer agents. A total of 160 subjects will be enrolled, treated by a single TACE 
therapy, and evaluated for 12 months. Including laboratory tests, the number of data 
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items per subject is approximately 80, and the number of total records per subject is 
approximately 15 (Table 1).   
 
Procedures of the clinical trial 
Preparation 
 
In the pilot test of our clinical trial process model, we prepared seven templates: 
Eligibility Criteria, Target Lesion, Protocol Treatment, Efficacy of Treatment based on 
the European Association for the Study of the Liver (EASL) standard [30], Efficacy of 
Treatment based on the Response Evaluation Criteria in Cancer of the Liver (RECICL) 
standard [31], Adverse Events based on CTCAE 4.0, and Follow-Up (Table 1). Codes 
and grades (i.e., EASL, RECIEL, CTCAE) were assigned by the investigators when 
they entered these data into the EMR using the clinical trial templates. Three types of 
ERS reports were used to check the clinical trial data: a List of Cases, each patient’s 
Case Registration Form, and the Case Report Form (Table 1). We show an example of 
the EMR template and progress notes from the EMR in Figure 2. 
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For the local data manager to verify the completeness and consistency of trial data, the 
Case Report Form can be identified. The Case Report Form summarises all the 
templates on one screen such that the integrity of all information for each patient can be 
assessed at a glance. The latest data for Eligibility Criteria, Target Lesion, Protocol 
Treatment, Efficacy of Treatment, and Follow-Up are displayed by item; Adverse 
Events are shown in sequence according to the name of the adverse event so that 
changes in the adverse event grade can be observed (Figure 3). 
 
Patient registration and random assignment of treatment arm 
 
Patients were registered and assigned randomly to a treatment arm in an independent 
registration centre outside of the EMR system. The investigator received the registration 
and assignment information and recorded it on the Eligibility Criteria template in the 
EMRs. 
 
Recording clinical trial data in EMRs 
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The investigator conducted the protocol treatment and evaluations according to the 
clinical pathways and recorded the results in templates. The results of required 
laboratory tests were extracted directly from the EMRs. 
 
Correction of data 
 
Clinical trials often require local-level administrative help with the increased workload 
[5, 32], but our model provides the local data manager with new responsibilities to 
ensure trial data quality. In the pilot study, a local data manager—a clinician at the 
participating site—manually checked the trial data for completeness and consistency 
using the Case Report Form on the ERS. When the local data manager found 
incomplete or inconsistent trial data, he asked the investigator to determine whether data 
should be corrected. The investigator added necessary data using the original EMR 
templates, thus storing a revision history in the EMRs. 
 
In the pilot study, the data in the EMR system create the edit checks and format the data 
for statistical analysis; thus a separate EDC system or the CDMS is unnecessary. We 
executed data checks manually to ensure that the latest medical records were correct. 
 19 
 
Extracting data for statistical analysis 
 
We used the ERS to extract data for the statistical analyses according to predefined data 
formatting and coding conventions. After the data were presented for statistical analysis 
in the CSV by the ERS, reports of all the data were prepared and archived in PDFs with 




We applied our new system to an actual clinical trial and evaluated its feasibility.  
 
Using the list of registered patients in the registration centre, we determined whether we 
could extract both the data by templates and the laboratory results of the registered 
patients in pre-designed forms. We verified that the data could be extracted correctly 
and found no unexpected problems. 
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Regarding the clinical staff workload, the investigators did not need to complete CRFs 
or enter data into an EDC system in addition to the EMRs. Among the prepared 
templates for the clinical trial, the only one that was added to the pilot study was 
Eligibility Criteria for patient registration. The investigators had to record information 
in the medical records for TACE, including the number of tumours, their diameter and 
extent of vascular invasion, and the therapeutic regimen, such as anticancer drug doses 
and embolised arteries in the liver. To record the necessary clinical information on a 
patient’s EMR, investigators used the templates based on the clinical pathways for 
TACE, and they checked the results of laboratory tests shown in the EMRs.  
 
Regarding the data quality control, as the data in the EMR templates were identical to 
those in the ERS, the use of the EDC system or the CDMS was also unnecessary. When 
investigators added information to EMRs, local data managers viewed reports in the 
Case Report Form automatically on the ERS. Local data managers check the data until 
all of the errors are corrected. In this way, the progress of the clinical trial and the 
situation for each patient could be assessed at a glance.  
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Figure 4 shows the procedural differences among a paper-based clinical trial, a clinical 
trial using the EDC system, and our new model. In contrast with conventional clinical 
trials, our model made it unnecessary to transcribe data from medical records to CRFs, 
to execute source data verification (SDV) at the participating site, to transport paper 
CRFs from the participating site to the coordinating centre, or to make double entries in 
the CDMS from paper CRFs. In addition, data checking was performed by the local data 
manager at the participating site, and supplemental data checking and data integration 




To execute clinical trials according to our model, specialised data must be accumulated 
from EMRs according to each clinical trial protocol. From a technical viewpoint, 
equipment for the flexible input functions, such as the EMR template, and efficient 
EMR retrieval systems are required. Consequently, trials must be planned from the 
stage of protocol development. The pilot test trial was planned to answer the practical 
questions that clinicians face in clinical practice. If a clinical trial is not practice-based 
[33-35], then it will not be easy to add medical records using a template. In our model, 
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the coordinating centre workload for data management and quality monitoring would be 
reduced. Instead, the workload of the local data manager at the participating site would 
be increased. In addition, in the test trial, every time errors were found in trial data using 
the Case Report Form on the ERS, the local data manager had to communicate with the 
investigator. In the future, more efficient local data-management methods will have to 
be established [36].  
 
Because the test trial used for the pilot study was executed in a single institution, it was 
not necessary to integrate the clinical trial data from multiple participating sites. We 
used the CSV format to present data for statistical analysis and the PDF format to 
archive the trial data at the participating site. To execute multi-institutional clinical trials, 
it will be necessary to standardise the descriptions in EMRs, use evidence-based clinical 
pathways, and create and validate templates across EMRs at all participating sites [37]. 
Currently, the accuracy of the information in EMRs may vary across sites [12]. For 
example, there are standard medical terminologies, such as ICD9, ICD10 [38], 
MedDRA [39], and SNOMED [40], but diagnosis or medications are associated with 
the payment of medical insurance, and use of classification schemas and terminology  
are at the discretion of clinicians at each site. Thus, the central coordinating centre will 
 23 
need to monitor and standardise the use of EMRs and integrate data provided across 
sites. In addition, a vendor-neutral and platform-independent standard format, such as 
the CDISC Operational Data Model (ODM) [41] and the CDISC Study Data Tabulation 
Model (SDTM) [42], will be needed to archive, transfer, and integrate trial data. The 
advantage is that the EMR system would not need to be retained in the future to access 




We proposed a new clinical trial process model by integrating it with clinical pathways 
and EMRs, which is the primary use of EMRs in a clinical trial. In a single-centre trial 
selected for the pilot study, our new model was integrated with the routine 
documentation of clinical practice and the procedures of clinical trials. Therefore, 
redundant data entries for the trial were avoided, and the burden on the investigators 
posed by the trial was minimised. 
 
The basis of our model is that the standardisation of clinical practice from clinical 
pathways can be applied as a treatment plan for a clinical trial; one primary use of the 
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EMR system could be to provide data for clinical trials. The most prominent 
characteristic of our model is that many data management tasks that typically are 
performed by the central coordinating centre are moved to the participating sites. In 
effect, the EMRs replace the EDC system and the CDMS. To maintain efficient data 
quality control, it is important to execute data management near the site of the data 
occurrence. The earlier an error is detected in a clinical trial, the sooner and more easily 
and cheaply it can be rectified [3]. Conventionally, the period from when an investigator 
executes protocol treatment to when the trial data are transcribed in the CRFs and 
checked by the data manager of the central coordinating centre spans several days (e.g., 
mean 5 days ranging 1 to 25 in our centre). In contrast, when investigators added 
information to the EMRs in the test trial, the data were immediately available to the 
local data manager for checking, which allowed rapid resolution of any anomalies 
introduced. Such real-time availability of trial data should reduce the time and cost of 
conducting clinical trials. 
 
In addition, in the eSDI proposal, the third scenario was called ‘Single Source Concept 
[4],: data need to be entered only once for multiple purposes (research, patient care, 
safety surveillance) within the context of existing regulations. The fourth scenario was 
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called ‘EMR Extraction and Investigator Verification’: a clinician would check EMRs 
for the necessary data for the clinical trial and extract and transfer the data to a sponsor. 
We believe that our new model fits these scenarios and that we have demonstrated an 
implementation model for eClinical trials based on the eSDI proposal. According to the 
eSDI scenario, Title 21 Part 11 of the Code of Federal Regulations [43] starts at the 
point of the creation of a clinical research record. In other words, it is not necessary to 
apply these regulations to the medical records at the site. The clinical research record is 
created at the point of electronic signature signing. When data are extracted from EMRs 
as clinical trial data, the migration of the data from EMRs to the clinical trial database 
must be validated at the participating site. In addition, the sponsor has to produce 
documents on how the procedures of the clinical trial follow all appropriate regulations. 
Because of the direct extraction of the clinical trial data from EMRs, our model may 
eliminate or minimize the need for source data verification. The audit plan should focus 
on the accuracy of the migration of data from EMRs to ensure that data are not changed 
in the extraction process and that patient confidentiality requirements are met [4]. We 
believe that by appropriating the efforts of source data verification in favour of 
validating the clinical trial process, the costs can be reduced and the efficiency of 
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Table 1. The Screen to Record Data for EMRs and the Data Check Screen.  
Screen to Record Data for EMRs 
Edit Check Screen 
Template Name Item Name 
Eligibility Criteria 
Informed consent 
List of Cases 
Case Registration Form  
Registration Number 
Date of Consent 
Result of Allocation 
Selection Criteria 1–8 
Exclusion Criteria 1–10 
Target Lesion 
Number 






Frequency of TACE 
Protocol Treatment 




Total Dose for TACE 
Tumour Location 








Efficacy of Treatment 
Recurrence Form 




Cause of Abdominal Pain 
Diarrhoea 
Cause of Diarrhoea 
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Nausea 
Cause of Nausea 
Vomiting 
Cause of Vomiting 
Fever 




Date of Progressive Disease 
Recurrence Form 
Treatment after Recurrence  
Conform to Protocol Treatment 
Reason of Change  
Date of Death 
EASL: European Association for the Study of the Liver; EMR: electronic medical 
record; PEIT: percutaneous ethanol injection therapy; RECICL: Response Evaluation 







Our new model of the clinical trial process.  
Figure 2. 
Electronic medical record (EMR) and the EMR template. The template is opened from 
within our EMR system. The template converts narrative information from progress 
notes, thereby making the information available as analytical data.  
Figure 3. 
The List of Cases and the Case Report Form. The Case Report Form can be consulted 
from the List of Case Registration Forms. The Case Report Form summarises all the 
templates on one screen so that all information can be assessed at a glance. EASL: 
European Association for the Study of the Liver; EMR: electronic medical record; 
RECICL: Response Evaluation Criteria in Cancer of the Liver. 
Figure 4. 
The pilot study revealed many advantages over a conventional clinical trial process, i.e., 
unnecessary to transfer information from medical records to the case report form, no 
need for source data verification at the participating site, unnecessary to transmit the 
case report form from the participating site to the coordinating centre, and unnecessary 
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to re-enter data into the clinical data management system (CDMS) from the paper case 
report form. In addition, data management in the coordinating centre was replaced with 
edit checks initiated by a local data manager at the participating site. CRF: case report 






















List of abbreviations 
CDISC: clinical data interchange standards consortium;  
CDMS: clinical data management system;  
CRF: case report form;  
CSV: comma separated values;  
CTCAE: common terminology criteria for adverse events;  
DWH: data warehouse;  
EASL: european association for the study of the liver;  
EDC: electronic data capture;  
EMR: electronic medical records;  
ERS: electronic medical records retrieval system;  
eSDI: electronic source data interchange;  
eSource: electronic source data;  
HTML: hypertext markup language;  
ICD: international classification of diseases;  
MedDRA: medical dictionary for regulatory activities;  
ODM: operational data model;  
OLAP: online analytical processing;  
 42 
PDF: portable document format;  
PEIT: percutaneous ethanol injection therapy;  
RECICL: response evaluation criteria in cancer of the liver;  
RFA: radiofrequency ablation;  
SDTM: study data tabulation model;  
SDV: source data verification;  
SNOMED: systematized nomenclature of medicine;  
TACE: transcatheter arterial chemoembolization;  
XML: extensible markup language; 
 
